| scholarly article | Q13442814 |
| P2093 | author name string | Carr VJ | |
| Lewin TJ | |||
| Carter NT | |||
| Fowler IL | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 443-455 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Patterns of current and lifetime substance use in schizophrenia | |
| P478 | volume | 24 |
| Q24197685 | Q24197685 |
| Q35148634 | "Clozapine makes me quite drowsy, so when I wake up in the morning those first cups of coffee are really handy": an exploratory qualitative study of excessive caffeine consumption among individuals with schizophrenia |
| Q40910972 | A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder. |
| Q34593373 | A case-linkage study of crime victimisation in schizophrenia-spectrum disorders over a period of deinstitutionalisation |
| Q43961939 | A comparison of schizophrenic patients with or without coexisting substance use disorder |
| Q39670906 | A comparison of the patterns of drug use among patients with and without severe mental illness |
| Q33909153 | A cross-sectional study of patients with and without substance use disorders in Community Mental Health Centres |
| Q100954434 | A large-scale genome-wide association study meta-analysis of cannabis use disorder |
| Q22251463 | A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors |
| Q33958615 | Addiction and schizophrenia |
| Q36118566 | Adolescence, schizophrenia and drug abuse: a window of vulnerability |
| Q36083997 | Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders |
| Q24635635 | Alcohol, nicotine, caffeine, and mental disorders |
| Q28186154 | An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response |
| Q43714107 | An evaluation of a pilot capacity building initiative for smoking cessation in social and community services: the Smoking Care project |
| Q36328573 | Assessing illicit drug use among adults with schizophrenia. |
| Q38001049 | Attitudes and perceptions towards substances among people with mental disorders: a systematic review |
| Q95319627 | Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia |
| Q36817167 | Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study |
| Q31095554 | Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? |
| Q34180323 | Cannabis and psychopathology : update 2004. |
| Q84618156 | Cannabis use and sensorimotor gating in patients with schizophrenia and healthy controls |
| Q34557027 | Cannabis use predicts future psychotic symptoms, and vice versa |
| Q37160448 | Cannabis, cannabinoids and schizophrenia: integration of the evidence |
| Q35936887 | Cannabis-associated psychosis: current status of research |
| Q47945952 | Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q51958090 | Comparisons between schizophrenia patients recruited from Australian general practices and public mental health services. |
| Q37075948 | Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders |
| Q36727032 | Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status |
| Q39812565 | Criminal Justice System Involvement Among People with Schizophrenia |
| Q51933665 | Criminality in men with major mental disorder with and without comorbid substance abuse. |
| Q44827846 | Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. |
| Q41823549 | Demographic and clinical correlates of substance abuse comorbidity in schizophrenia. |
| Q34744036 | Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review |
| Q38076103 | Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis |
| Q48722624 | Does giving up substance use work for patients with psychosis? A systematic meta-analysis |
| Q44777019 | Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences |
| Q37335180 | Dual diagnosis and psychosocial interventions--introduction and commentary |
| Q92001568 | Dual diagnosis in a Dublin tertiary addiction centre - A cross-sectional study |
| Q46491009 | Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial |
| Q34128935 | Effects of cannabis use on age at onset in schizophrenia and bipolar disorder |
| Q39820721 | Effects of Δ-THC on Working Memory: Implications for Schizophrenia? |
| Q37285509 | Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis |
| Q35897524 | Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other disease-related vulnerabilities: emerging evidence |
| Q40812818 | Experience, knowledge and attitudes of mental health staff regarding patients' problematic drug and alcohol use. |
| Q39078730 | Factors affecting smoking cessation efforts of people with severe mental illness: a qualitative study |
| Q64057153 | Gene Expression Profiles Associated with Brain Aging are Altered in Schizophrenia |
| Q42620833 | Group intervention for coexisting psychosis and substance use disorders in rural Australia: outcomes over 3 years |
| Q36008594 | Hospitalisation of severely mentally ill patients with and without problematic substance use before and during Assertive Community Treatment: an observational cohort study |
| Q51694214 | Identifying co-occurring substance use disorders in community mental health centres. Tailored approaches are needed. |
| Q36087073 | Illicit drug use in heavy smokers with and without schizophrenia |
| Q47553301 | Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: Data from the national RAISE-ETP study. |
| Q43733463 | Impediments to screening for hazardous alcohol use and dependence in general hospital psychiatric inpatients |
| Q48246767 | Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls. |
| Q44819773 | Meta-analysis of self-reported substance use compared with laboratory substance assay in general adult mental health settings. |
| Q44278946 | Missed opportunities in the field: caring for clients with co-morbidity problems |
| Q44115969 | Motivational interviewing among psychiatric in-patients with substance use disorders |
| Q42748636 | Motives for substance use among young people seeking mental health treatment |
| Q47556638 | Online Communication about Depression and Anxiety among Twitter Users with Schizophrenia: Preliminary Findings to Inform a Digital Phenotype Using Social Media |
| Q36080004 | Oxidative Stress-Induced Response of Some Endogenous Antioxidants in Schizophrenia. |
| Q34516286 | Perceived reasons for and consequences of substance abuse among patients with psychosis |
| Q30455113 | Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia |
| Q80194480 | Pharmacotherapy for schizophrenia and co-occurring substance use disorders |
| Q34675579 | Prevalence and socio-demographic risk factors associated with psychoactive substance use in psychiatric out-patients of a tertiary hospital in Nigeria |
| Q37449097 | Prevalence of alcohol use disorders in schizophrenia--a systematic review and meta-analysis |
| Q34021649 | Prevalence of psychosis/substance abuse comorbidity. Clinical-epidemiological findings from different treatment settings in a large German city |
| Q38996589 | Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders |
| Q43042570 | Providing nicotine dependence treatment to psychiatric inpatients: the views of Australian nurse managers. |
| Q46042036 | Psychiatric correlates of past incarceration in the national co-morbidity study replication |
| Q58164163 | Psychiatric rehabilitation of schizophrenia: Unresolved issues, current trends, and future directions |
| Q90734187 | Psychoactive substance use among outpatients with severe mental illness: A comparative study |
| Q47205789 | Psychoactive substance use in specialized psychiatric care patients |
| Q37328436 | Psychosocial treatments for people with co-occurring severe mental illness and substance misuse: systematic review |
| Q34235419 | Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis |
| Q48444646 | Reasons for cannabis use in psychosis |
| Q48314627 | Reasons for cannabis use: patients with schizophrenia versus matched healthy controls |
| Q22252274 | Reasons for increased substance use in psychosis |
| Q46602237 | Reduced tumor growth in a mouse model of schizophrenia, lacking the dopamine transporter |
| Q45079589 | Reflections of young people who have had a first episode of psychosis: what attracted them to use alcohol and illicit drugs? |
| Q37244113 | Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia |
| Q51968074 | Risk factors for HIV/AIDS and hepatitis C among the chronic mentally ill. |
| Q47553353 | Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. |
| Q57403357 | Schizophrenia and Substance Abuse Co-Morbidity |
| Q36610560 | Schizophrenia and Suicide Attempts: Findings from a Representative Community-Based Canadian Sample |
| Q38765239 | Schizophrenia: genetics, prevention and rehabilitation |
| Q80214586 | Schizotypy, marijuana, and differential item functioning |
| Q48736672 | Significant relationship between lifetime alcohol use disorders and suicide attempts in an Australian schizophrenia sample. |
| Q44109885 | Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders |
| Q30364687 | Social Stress and Psychosis Risk: Common Neurochemical Substrates? |
| Q52000103 | Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. |
| Q37705759 | Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use |
| Q57550143 | Substance Use in Adolescent Psychiatric Outpatients: Self-Report, Health Care Providers' Clinical Impressions, and Urine Screening |
| Q59668672 | Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity |
| Q34201663 | Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden |
| Q47336047 | Substance abuse, temperament and suicide risk: evidence from a case-control study |
| Q36092716 | Substance use disorder and schizophrenia: prevalence and sociodemographic characteristics in the Latin American population |
| Q34130842 | Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry |
| Q43471662 | Substance use disorders among psychotic patients admitted to inpatient psychiatric care |
| Q39501354 | Substance use disorders in men presenting to a psychosexual clinic. |
| Q43145195 | Substance use disorders in schizophrenia--clinical implications of comorbidity |
| Q61242681 | Suicidal behavior in schizophrenia and schizoaffective disorder |
| Q56910062 | Suicide Attempts in an African Schizophrenia Population: An Assessment of Demographic Risk Factors |
| Q38192896 | Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. |
| Q44487800 | Testing hypotheses about the relationship between cannabis use and psychosis |
| Q34607377 | The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research |
| Q36202210 | The Interrater Reliability of Nursing Outcome Classification (NOC): "Caregiver Performance: Direct Care". |
| Q36059843 | The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use. |
| Q45737010 | The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis |
| Q45778447 | The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC). |
| Q83194789 | The long-term level of functioning in patients admitted for psychotic disorders with and without substance abuse |
| Q37161528 | The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study |
| Q57839094 | Tobacco, Caffeine, Alcohol and Illicit Substance Use Among Consumers of a National Psychiatric Disability Support Service |
| Q57839085 | Tobacco, caffeine, alcohol and illicit substance use among consumers of a national community managed mental health service |
| Q33615443 | Total smoking bans in psychiatric inpatient services: a survey of perceived benefits, barriers and support among staff. |
| Q38111474 | Treatment of co-occurring psychotic and substance use disorders |
| Q36228225 | Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? |
| Q45767391 | Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors |
| Q33996635 | Variance of gene expression identifies altered network constraints in neurological disease |
| Q37326415 | Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review |
| Q33703935 | Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders |
| Q33223628 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia |
Search more.